HCYT

H-CYTE, Inc. [HCYT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

HCYT Stock Summary

In the News

HCYT Financial details

Company Rating
-
Market Cap
624.98K
Income
-9.09M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
10 Aug 2023
P/E
-0.05
Forward P/E
-
PEG
0.02
P/S
8.46
P/B
-0.05
P/C
-
P/FCF
-0.45
Quick Ratio
0.01
Current Ratio
0.03
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-23.87
EPS next Y
-
EPS next Q
-
EPS this Y
46.05%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-25.04%
Revenue last 5Y
-11.13%
Revenue Q/Q
-
EPS Q/Q
-87.48%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-3735%
ROE
147%
ROC
0.51%
Gross Margin
-242%
Oper. Margin
-6396%
Profit Margin
-17657%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.5002-7.0
52W High
-
52W Low
-
RSI
-
Rel Volume
1.86
Avg Volume
796
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
0.51844
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
3V64.DE
VFINX
FB2A.DE
M&M.NS
1YD.DE
Same Sector
ALNOV.PA
RPGLIFE.NS
BAFNAPH.NS
AVAH
MAHLY
Check Those
ACGL
AAME
GWEIX
HIMVX
ADTX
Similar Market Cap
PVNNF
3SNF.L
MNRG.L
REMI
BDPT

Company Profile

Healthcare Biotechnology
  • Volume Average 796
  • Market Capitalization 624.98K
  • Employee 2
  • CEO Mr. Michael W. Yurkowsky
  • Headquarters Tampa,FL,US
  • IPO Date 2014-12-19
  • Website https://www.hcyte.com

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.